Actavia Life Sciences, Inc. reported earnings results for the full year ended September 30, 2023. For the full year, the company reported net loss was USD 4.44 million compared to USD 0.686588 million a year ago. Basic loss per share from continuing operations was USD 0.01 compared to USD 0.01 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0125 USD | -27.75% | 0.00% | +62.34% |
1st Jan change | Capi. | |
---|---|---|
+62.34% | 13.35M | |
+2.97% | 108B | |
+10.21% | 105B | |
+1.57% | 23.46B | |
-12.77% | 21.72B | |
-7.05% | 18.64B | |
-37.64% | 17.45B | |
-6.50% | 17.19B | |
+6.00% | 13.99B | |
+37.20% | 12.53B |
- Stock Market
- Equities
- RASP Stock
- News Actavia Life Sciences, Inc.
- Actavia Life Sciences, Inc. Reports Earnings Results for the Full Year Ended September 30, 2023